There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Nuvectis Pharma (NVCT – Research Report) and Werewolf Therapeutics (HOWL – Research Report) with bullish sentiments.
Nuvectis Pharma (NVCT)
In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Nuvectis Pharma, with a price target of $21.00. The company’s shares closed last Thursday at $14.02.
According to TipRanks.com, Pantginis ‘ ranking currently consits of 0 on a 0-5 ranking scale, with an average return of
Currently, the analyst consensus on Nuvectis Pharma is a Moderate Buy with an average price target of $21.00.
See today’s best-performing stocks on TipRanks >>
Werewolf Therapeutics (HOWL)
In a report released today, Andres Y. Maldonado from H.C. Wainwright reiterated a Buy rating on Werewolf Therapeutics, with a price target of $15.00. The company’s shares closed last Thursday at $2.57.
According to TipRanks.com, Maldonado has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Werewolf Therapeutics with a $12.00 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on NVCT:
- Nuvectis Pharma announces initiation of NXP9000 Phase 1a trial
- Nuvectis Pharma to Host KOL Event to Discuss Its Two Precision Medicine Clinical-Stage Drug Candidates, NXP800 and NXP900
- Nuvectis Pharma Announces Participation at Upcoming Investor Conferences
- Nuvectis Pharma Announces Orphan Drug Designation Granted by the FDA to NXP800 for the Treatment of Cholangiocarcinoma
- Nuvectis Pharma announces ODD granted by FDA to NXP800
